AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Passes Above 50-Day Moving Average – Here’s What Happened

AB Corporate Bond ETF (NASDAQ:EYEG)’s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $35.26 and traded as high as $35.29. AB Corporate Bond ETF shares last traded at $35.2240, with a volume of 17 shares changing hands.

AB Corporate Bond ETF Stock Performance

The firm has a fifty day simple moving average of $35.26 and a 200 day simple moving average of $35.59. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The stock has a market cap of $28.21 million, a price-to-earnings ratio of -20.99 and a beta of 0.17.

AB Corporate Bond ETF Increases Dividend

The company also recently declared a monthly dividend, which was paid on Thursday, June 4th. Shareholders of record on Monday, June 1st were issued a $0.1415 dividend. This is a positive change from AB Corporate Bond ETF’s previous monthly dividend of $0.14. The ex-dividend date of this dividend was Monday, June 1st. This represents a c) annualized dividend and a yield of 4.8%. AB Corporate Bond ETF’s payout ratio is currently -102.98%.

Hedge Funds Weigh In On AB Corporate Bond ETF

Several large investors have recently added to or reduced their stakes in EYEG. Kestra Advisory Services LLC acquired a new position in AB Corporate Bond ETF in the 4th quarter valued at approximately $34,000. Jane Street Group LLC acquired a new position in shares of AB Corporate Bond ETF in the 2nd quarter worth approximately $232,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of AB Corporate Bond ETF by 32.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after buying an additional 38,685 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.